Clinical Trial

Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Study acronym: SORT-COPD
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a phase 1, first-in-human, open-label, non-randomized, dose escalation safety study of 18 participants, between 39 and 69 years of age, with mild to moderate chronic obstructive pulmonary disease, treated with SORT-COPD (SMS cells). The primary objective of this study is to determine the safety of SORT-COPD (SMS cells) at three doses in people with chronic obstructive pulmonary disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-15; most recent amendment 2026-02-09.
Status change: Active, Not Recruiting → Recruiting 2025-05-26
Trial Details
NCT Number NCT06986070
Lead Sponsor SMSbiotech
Conditions Chronic Obstructive Lung Disease
Enrollment 18 participants
Start Date 2025-06-13
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-11